dr. reddy's labs glp-1 receptor agonist medications India's Dr Reddy's plans to launch generic obesity drugs in 87 countries next year, CEO says

Dr. Reddy's Laboratories has entered the fast-growing GLP-1 therapy segment with the launch of its semaglutide generic, Obeda, for Type 2 diabetes in India's ₹1,446 crore market. 𝐑𝐞𝐚𝐝 𝐟𝐮𝐥𝐥 𝐚𝐫𝐭𝐢𝐜𝐥𝐞 𝐨𝐧 𝐨𝐮𝐫

22.13

★★★★☆4.8 (126)

Dr. Reddy's Laboratories has received approval from Health Canada for its generic semaglutide injection, strengthening the Indian drugmaker's presence in the fast-growing global market for GLP-1 diabetes therapies. The company said on

29.55

★★★★★4.9 (98)

Dr. Reddy's Laboratories said on Friday that it will change the brand name of its semaglutide drug from "Olymviq" to "Olymra" after the Delhi High Court flagged phonetic and visual similarity with

29.15

★★★★★5.0 (157)

GLP-1 now available as tablets? Semaglutide will now be more accessible than ever as Dr. Reddy's gets nod to roll out generic oral semaglutide drug Meryl Dsouza shares all the details -

27.31

★★★★★4.7 (84)

With the launch of Obeda®, India's first DCGI-approved semaglutide injection for Type 2 Diabetes, we are excited to support diabetes care in India with high-quality, accessible and affordable treatment. In a head-to-head

21.66

★★★★★4.9 (203)

Dr. Reddy's wins India nod for generic Ozempic (RDY:NYSE)

24.67

★★★★★5.0 (176)

Dr Reddy's Launches Oral Semaglutide in India

22.84

★★★★★4.8 (132)